Published in Infect Immun on September 01, 1996
IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci (2012) 2.15
Bacterial perturbation of cytokine networks. Infect Immun (1998) 1.96
Molecular functions of syndecan-1 in disease. Matrix Biol (2011) 1.47
Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. J Biol Chem (2011) 1.29
Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J Clin Invest (1997) 1.28
ZmpB, a novel virulence factor of Streptococcus pneumoniae that induces tumor necrosis factor alpha production in the respiratory tract. Infect Immun (2003) 1.12
Molecular and cellular mechanisms of ectodomain shedding. Anat Rec (Hoboken) (2010) 1.08
Two allelic forms of the aureolysin gene (aur) within Staphylococcus aureus. Infect Immun (2000) 1.08
Recognition sequences and structural elements contribute to shedding susceptibility of membrane proteins. Biochem J (2001) 1.02
Molecular and functional characterization of a ToxR-regulated lipoprotein from a clinical isolate of Aeromonas hydrophila. Infect Immun (2006) 1.00
Calprotectin inhibits matrix metalloproteinases by sequestration of zinc. Mol Pathol (2001) 0.99
Purification and characterization of two distinct metalloproteases secreted by the entomopathogenic bacterium Photorhabdus sp. strain Az29. Appl Environ Microbiol (2004) 0.99
The Pseudomonas aeruginosa LasB metalloproteinase regulates the human urokinase-type plasminogen activator receptor through domain-specific endoproteolysis. Infect Immun (2007) 0.92
Interleukin-6: a new therapeutic target in systemic sclerosis? Clin Transl Immunology (2013) 0.81
Iron and zinc exploitation during bacterial pathogenesis. Metallomics (2015) 0.77
The interplay of extracellular matrix and microbiome in urothelial bladder cancer. Nat Rev Urol (2015) 0.76
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem (1983) 206.01
Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature (1994) 4.78
Metalloproteinase-mediated release of human Fas ligand. J Exp Med (1995) 3.53
Membrane-anchored growth factors. Annu Rev Biochem (1993) 3.26
Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature (1994) 3.15
Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J (1994) 2.83
Bacterial extracellular zinc-containing metalloproteases. Microbiol Rev (1993) 2.69
Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature (1994) 2.53
Bacterial phospholipases C. Microbiol Rev (1993) 2.34
Membrane proteins with soluble counterparts: role of proteolysis in the release of transmembrane proteins. Biochemistry (1991) 2.34
The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol (1994) 2.26
The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol (1993) 2.01
Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol (1992) 1.94
A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med (1995) 1.76
Physiological enzymatic cleavage of leukocyte membrane molecules. Immunol Today (1995) 1.72
A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol (1995) 1.70
Structure-function analysis of human IL-6 receptor: dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130. EMBO J (1993) 1.46
Crystal structure of the 50 kDa metallo protease from Serratia marcescens. J Mol Biol (1994) 1.35
A simple method for the purification of human peripheral blood monocytes. A substitute for Sepracell-MN. J Immunol Methods (1991) 1.17
Role of elastase as a virulence factor in experimental Pseudomonas aeruginosa infection in mice. Microb Pathog (1992) 0.99
Interleukin-6 (IL-6) antagonism by soluble IL-6 receptor alpha mutated in the predicted gp130-binding interface. J Biol Chem (1995) 0.99
The induction of ornithine decarboxylase by the tumor promoter TPA is controlled at the post-transcriptional level in murine Swiss 3T3 fibroblasts. Biochem Biophys Res Commun (1987) 0.96
Recombinant soluble human interleukin-6 receptor. Expression in Escherichia coli, renaturation and purification. Eur J Biochem (1993) 0.96
Proteinaceous bacterial toxins and pathogenesis of sepsis syndrome and septic shock: the unknown connection. Med Microbiol Immunol (1994) 0.90
Role of bradykinin in microbial infection: enhancement of septicemia by microbial proteases and kinin. Agents Actions Suppl (1993) 0.85
Small-angle x-ray scattering study of metal ion-induced conformational changes in Serratia protease. J Biol Chem (1992) 0.79
On the mechanism of membrane damage by Staphylococcus aureus alpha-toxin. J Cell Biol (1981) 4.06
Escherichia coli hemolysin may damage target cell membranes by generating transmembrane pores. Infect Immun (1986) 3.94
Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity (2001) 3.27
Mechanism of membrane damage by streptolysin-O. Infect Immun (1985) 3.26
Enzyme-linked immunoassay for detection of PCR-amplified DNA of legionellae in bronchoalveolar fluid. J Clin Microbiol (1995) 3.04
Delivery of proteins into living cells by reversible membrane permeabilization with streptolysin-O. Proc Natl Acad Sci U S A (2001) 2.67
Production of listeriolysin by beta-hemolytic strains of Listeria monocytogenes. Infect Immun (1986) 2.66
Isolation and identification of two hemolytic forms of streptolysin-O. Infect Immun (1984) 2.57
Novel path to apoptosis: small transmembrane pores created by staphylococcal alpha-toxin in T lymphocytes evoke internucleosomal DNA degradation. Infect Immun (1994) 2.47
I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol (1997) 2.47
Staphylococcal alpha-toxin: oligomerization of hydrophilic monomers to form amphiphilic hexamers induced through contact with deoxycholate detergent micelles. Proc Natl Acad Sci U S A (1981) 2.38
A guide to the use of pore-forming toxins for controlled permeabilization of cell membranes. Med Microbiol Immunol (1993) 2.37
Damage to mammalian cells by proteins that form transmembrane pores. Rev Physiol Biochem Pharmacol (1987) 2.36
Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem (2001) 2.30
The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol (1994) 2.26
Damage to cell membranes by pore-forming bacterial cytolysins. Prog Allergy (1988) 2.23
Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem (1996) 2.19
Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J Immunol (1998) 2.16
Staphylococcal alpha-toxin, streptolysin-O, and Escherichia coli hemolysin: prototypes of pore-forming bacterial cytolysins. Arch Microbiol (1996) 2.11
Molecular nature of the complement lesion. Proc Natl Acad Sci U S A (1978) 2.09
Staphylococcal alpha-toxin kills human keratinocytes by permeabilizing the plasma membrane for monovalent ions. Infect Immun (1993) 2.09
Potassium-inhibited processing of IL-1 beta in human monocytes. EMBO J (1995) 2.08
Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation (2001) 2.02
Correlation between toxin binding and hemolytic activity in membrane damage by staphylococcal alpha-toxin. Infect Immun (1984) 2.01
The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol (1993) 2.01
Membrane damage by complement. Biochim Biophys Acta (1983) 2.00
Complement lysis: the ultrastructure and orientation of the C5b-9 complex on target sheep erythrocyte membranes. Scand J Immunol (1978) 1.95
Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol (2006) 1.95
Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol (1992) 1.94
Structure of an extracellular gp130 cytokine receptor signaling complex. Science (2001) 1.94
Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. J Clin Microbiol (1995) 1.94
Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J Immunol (1986) 1.83
Isolation and characterization of a pigmentless-conidium mutant of Aspergillus fumigatus with altered conidial surface and reduced virulence. Infect Immun (1997) 1.82
IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle (2005) 1.79
Subcytocidal attack by staphylococcal alpha-toxin activates NF-kappaB and induces interleukin-8 production. Infect Immun (2001) 1.71
A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol (1995) 1.70
TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol (1999) 1.69
The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med (1996) 1.65
Protein sorting in Plasmodium falciparum-infected red blood cells permeabilized with the pore-forming protein streptolysin O. Biochem J (1996) 1.64
Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation (2001) 1.64
Escherichia coli haemolysin forms voltage-dependent ion channels in lipid membranes. Biochim Biophys Acta (1987) 1.61
An evaluation of 2,5-norbornadiene as a reversible inhibitor of ethylene action in deepwater rice. Plant Physiol (1987) 1.60
Transmembrane beta-barrel of staphylococcal alpha-toxin forms in sensitive but not in resistant cells. Proc Natl Acad Sci U S A (1997) 1.58
Staphylococcal alpha-toxin-induced PGI2 production in endothelial cells: role of calcium. Am J Physiol (1985) 1.57
Mechanism of complement cytolysis and the concept of channel-forming proteins. Philos Trans R Soc Lond B Biol Sci (1984) 1.57
Influence of the terminal complement-complex on reperfusion injury, no-reflow and arrhythmias: a comparison between C6-competent and C6-deficient rabbits. Cardiovasc Res (1996) 1.55
Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci U S A (1998) 1.51
Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J (1998) 1.50
Isolation of the terminal complement complex from target sheep erythrocyte membranes. Biochim Biophys Acta (1976) 1.47
Complement activation by oxidatively modified low-density lipoproteins. Eur J Clin Invest (1999) 1.47
Helicobacter sp. strain Mainz isolated from an AIDS patient with septic arthritis: case report and nonradioactive analysis of 16S rRNA sequence. J Clin Microbiol (1994) 1.45
Staphylococcal alpha-toxin elicits hypertension in isolated rabbit lungs. Evidence for thromboxane formation and the role of extracellular calcium. J Clin Invest (1984) 1.43
Minimal requirements for exocytosis. A study using PC 12 cells permeabilized with staphylococcal alpha-toxin. J Biol Chem (1985) 1.40
Detection of amphiphilic proteins and peptides in complex mixtures. Charge-shift crossed immunoelectrophoresis and two-dimensional charge-shift electrophoresis. Biochim Biophys Acta (1977) 1.38
The terminal membrane C5b-9 complex of human complement. Evidence for the existence of multiple protease-resistant polypeptides that form the trans-membrane complement channel. J Immunol (1980) 1.36
Staphylococcal alpha-toxin-induced vascular leakage in isolated perfused rabbit lungs. Lab Invest (1990) 1.35
Immunohistochemical study of the C5b-9 complex of complement in human kidneys. Kidney Int (1986) 1.33
Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood (1998) 1.32
Shedding of interleukin-6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur J Biochem (2000) 1.32
Identification with monoclonal antibodies of hemolysin produced by clinical isolates of Escherichia coli. J Clin Microbiol (1987) 1.32
Staphylococcus aureus alpha-toxin. Dual mechanism of binding to target cells. J Biol Chem (1991) 1.30
Mechanism of leukotriene generation in polymorphonuclear leukocytes by staphylococcal alpha-toxin. Infect Immun (1987) 1.30
STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut (2006) 1.30
Colorimetric susceptibility testing for Aspergillus fumigatus: comparison of menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide and Alamar blue tests. J Clin Microbiol (1996) 1.29
Use of a monoclonal antibody to determine the mode of transmembrane pore formation by streptolysin O. Infect Immun (1986) 1.28
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis immunoblotting as a serological tool in the diagnosis of syphilitic infections. J Clin Microbiol (1985) 1.27
Recovery of human fibroblasts from attack by the pore-forming alpha-toxin of Staphylococcus aureus. Microb Pathog (1994) 1.27
Quantitative study of the binding and hemolytic efficiency of Escherichia coli hemolysin. Infect Immun (1989) 1.27
Acute-phase response factor, increased binding, and target gene transcription during liver regeneration. Gastroenterology (1996) 1.26
Binding and partial inactivation of Staphylococcus aureus alpha-toxin by human plasma low density lipoprotein. J Biol Chem (1983) 1.26
Cytocidal effects of Escherichia coli hemolysin on human T lymphocytes. Infect Immun (1993) 1.25
Development of a human interleukin-6 receptor antagonist. J Biol Chem (1994) 1.25
Helicobacter pylori: clonal population structure and restricted transmission within families revealed by molecular typing. J Clin Microbiol (2000) 1.25
Potassium regulates IL-1 beta processing via calcium-independent phospholipase A2. J Immunol (2000) 1.25
Characterization of a catalase-negative methicillin-resistant Staphylococcus aureus strain. J Clin Microbiol (2007) 1.25
Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol (1998) 1.23
Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob Agents Chemother (1994) 1.23
Human endothelial cell activation and mediator release in response to the bacterial exotoxins Escherichia coli hemolysin and staphylococcal alpha-toxin. J Immunol (1997) 1.23
Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation (1997) 1.23
Selective killing of human monocytes and cytokine release provoked by sphingomyelinase (beta-toxin) of Staphylococcus aureus. Infect Immun (1996) 1.22
The importance of shedding of membrane proteins for cytokine biology. Eur Cytokine Netw (2000) 1.21
Molecular architecture of a toxin pore: a 15-residue sequence lines the transmembrane channel of staphylococcal alpha-toxin. EMBO J (1996) 1.21
Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab Invest (1989) 1.21
Monoclonal antibodies against neoantigens of the terminal C5b-9 complex of human complement. Biosci Rep (1985) 1.21
Cytotoxic action of Serratia marcescens hemolysin on human epithelial cells. Infect Immun (1999) 1.21
Quantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium. Clin Exp Immunol (1990) 1.20
Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol (1998) 1.20
Staphylococcal alpha-toxin: formation of the heptameric pore is partially cooperative and proceeds through multiple intermediate stages. Biochemistry (1997) 1.19
Sensitive ELISA for quantitating the terminal membrane C5b-9 and fluid-phase SC5b-9 complex of human complement. J Immunol Methods (1987) 1.19
In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6. J Immunol (1998) 1.19
Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice. Am J Pathol (1998) 1.19
Staphylococcus aureus alpha-toxin. Production of functionally intact, site-specifically modifiable protein by introduction of cysteine at positions 69, 130, and 186. J Biol Chem (1993) 1.19
Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding. J Biol Chem (1993) 1.18
Surgical procedure affects physiological parameters in rat myocardial ischemia: need for mechanical ventilation. Am J Physiol (1999) 1.17
C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore. J Immunol (1986) 1.16